Peptides Mentioned on the Joe Rogan Podcast (JRE)
No media figure has done more to bring peptide therapy to a mainstream audience than Joe Rogan. Across multiple JRE episodes — most notably with Stanford neuroscientist Andrew Huberman and healthcare entrepreneur Brigham Buhler — Rogan has discussed his personal peptide protocol, the "Wolverine Stack," GH secretagogues, and the regulatory war over compounded peptide access. Below is a full breakdown of every compound that has been named, what was actually said, and what the published research supports.
BPC-157 for elbow tendinitis; academic framing of peptide research
First deep dive on peptide access, ban list, and clinical stacks
Health optimization deep dive — peptides in longevity context
Rogan describes the Wolverine Stack to a mainstream audience
Peptide ban reversal, Eli Lilly contradiction, regulatory optimism
Brigham Buhler
Founder, Ways2Well & ReviveRx Pharmacy · JRE #2079 (Dec 2023) · JRE #2469 (March 2026)
A 15-year healthcare industry veteran and founder of Ways2Well — a functional and regenerative medicine clinic — and ReviveRx, a compounding pharmacy. Buhler is one of the most informed voices on the regulatory and clinical side of peptide therapy, having submitted 17 FOIA requests to the FDA regarding the peptide ban. His JRE appearances focused heavily on the gap between the research evidence base and the regulatory treatment of peptides, with specific attention to what he sees as pharmaceutical industry influence in FDA policy.
Andrew Huberman
Stanford Neuroscientist, Host of Huberman Lab · JRE #1673 · JRE #1683 (2021) · JRE #2195 (Aug 2024)
Professor of neurobiology at Stanford School of Medicine and host of the Huberman Lab podcast. Huberman brought an academic framing to peptide discussions that differed from most biohacker content — he was consistent in noting where human clinical data is lacking while still engaging seriously with the mechanistic research. His episodes with Rogan introduced BPC-157 to an enormous mainstream audience in 2021.
BPC-157 + TB-500. Named after the X-Men character's near-instant healing ability. Rogan described it on JRE #2440 as letting you "heal like you're a fucking six-year-old." The most widely referenced peptide stack in the JRE universe — focused entirely on injury recovery and connective tissue repair.
Wolverine Stack + GHK-Cu + KPV. Introduced by Buhler on JRE #2079. Adds a skin quality and anti-inflammatory layer to the recovery stack. Buhler described patients reporting visible improvements in skin texture and reduced scarring alongside the structural healing benefits.
Ipamorelin + CJC-1295, referenced alongside BPC-157 and Thymosin Alpha-1 as Rogan's personal protocol. Buhler described this combination as the primary alternative to exogenous growth hormone for patients seeking body composition, sleep quality, and recovery benefits without synthetic HGH.
Every Peptide — What Was Said & What the Research Shows
Each compound listed below has been named or discussed across the JRE episodes above. For each one: a summary of what was said on-air, an objective research overview, and a direct link to source it from Base Peptides.
BPC-157
What Was Said on JRE
BPC-157 is the peptide most associated with Joe Rogan personally. In JRE #1683, Rogan credited it with resolving his stubborn elbow tendinitis — an injury from weightlifting and martial arts that had resisted other treatments — in approximately two weeks. Huberman explained the mechanism in scientific terms: BPC-157 acts as a "repair signal" that encourages fibroblasts — the cells that build connective tissue — to migrate to injury sites and begin rebuilding. Huberman was also the one who added the honest caveat: "There isn't any clinical data for BPC-157. It's all animals." That transparency is a key reason the discussion landed credibly with a broad audience. Brigham Buhler added that adverse effects from BPC-157 are "almost exclusively found in black-market peptides" with contamination or purity issues — reinforcing the importance of sourcing from regulated compounding pharmacies.
What It Is
A synthetic 15-amino-acid peptide fragment derived from a protein found in human gastric juice. BPC-157 upregulates growth hormone receptors, modulates the nitric oxide system for improved blood flow, and activates the FAK-paxillin pathway involved in cell migration and wound closure. It also has systemic stabilizing effects via the dopamine and serotonin systems.
Key Research & Context
- Tendon-to-bone healing — among the best-studied applications in rodent models
- Gut mucosal repair — shown to reduce colitis severity and accelerate GI healing
- Nitric oxide pathway modulation for improved vascular supply to injury sites
- Rogan's personal use: resolved chronic elbow tendinitis in ~2 weeks
Research context: No completed human clinical trials as of 2025. Huberman stated this explicitly on air. All human efficacy data is extrapolated from animal studies and practitioner anecdotal reports. Research compound only.
TB-500 (The Wolverine Stack)
What Was Said on JRE
TB-500 has become inseparable from BPC-157 in the JRE orbit. Buhler introduced the combination framework in his first appearance, and by January 2026 — in a surprise appearance on JRE #2440 with Matt Damon and Ben Affleck — Rogan was describing the BPC-157 + TB-500 combination as the ultimate recovery protocol, saying it lets you "heal like you're a fucking six-year-old." This pairing became widely known as the "Wolverine Stack" — named after the X-Men character's near-instant tissue regeneration. The rationale, as Buhler explained it: BPC-157 works at the repair site itself, while TB-500 improves blood flow and sends the cellular resources needed to rebuild damaged tissue matrix.
What It Is
A synthetic fragment of Thymosin Beta-4, a 43-amino-acid protein present in virtually every nucleated cell. TB-500 promotes healing through actin regulation, enabling rapid cell migration to injury sites. It also stimulates angiogenesis, reduces inflammatory signaling, and distributes systemically — meaning it reaches injuries regardless of where it is injected.
Key Research & Context
- The "Wolverine Stack" — BPC-157 + TB-500 is the combination Rogan has most publicly endorsed
- Systemic distribution — unlike locally-acting peptides, TB-500 reaches injuries from any injection site
- Cardiac tissue protection research — studied in ischemia-reperfusion models
- Rogan recommended it on JRE #2440 to a mainstream audience including Matt Damon and Ben Affleck
Research context: Animal studies raise a concern about potential acceleration of dormant tumor growth in certain contexts. No completed human clinical trials for recovery applications.
Ipamorelin
What Was Said on JRE
Ipamorelin was cited by Buhler as one of the most clinically useful peptides in his practice — and it has appeared in multiple accounts of Rogan's own supplement stack. In a 2022 Flagrant podcast appearance, Rogan described his personal peptide protocol as BPC-157, Ipamorelin, and Thymosin Alpha-1. Buhler described Ipamorelin's appeal in clinical terms: it selectively stimulates GH release without meaningfully elevating cortisol or prolactin — the side effects that made older GHRPs like GHRP-6 less desirable. This selectivity makes it one of the most used GH secretagogues in functional medicine practice.
What It Is
A selective growth hormone secretagogue that acts as a ghrelin receptor agonist. Unlike older GHRPs, ipamorelin does not significantly co-secrete cortisol or prolactin, making it tolerable for longer protocols. It stimulates physiologic GH pulses that promote fat metabolism, muscle preservation, improved sleep quality, and connective tissue repair.
Key Research & Context
- Part of Rogan's personal stack alongside BPC-157 and Thymosin Alpha-1
- Selective GH release — no significant cortisol or prolactin elevation (key advantage over GHRP-6)
- Commonly stacked with CJC-1295 for synergistic GH pulse amplification
- Clinical use in sleep quality improvement, recovery, body composition, and anti-aging protocols
Research context: Was included in the FDA's compounding ban list. Regulatory access has varied. Long-term suppression of endogenous GH production with continuous use is a theoretical concern worth monitoring.
CJC-1295
What Was Said on JRE
CJC-1295 was discussed primarily as the natural companion to Ipamorelin. Buhler explained that CJC-1295 and Ipamorelin work through different but complementary mechanisms — CJC-1295 acts on GHRH receptors while Ipamorelin acts on ghrelin receptors — and that combining them produces a synergistic GH pulse that significantly exceeds what either achieves alone. He described this combination as one of the most commonly prescribed stacks at his clinic for patients seeking GH support without exogenous hormone therapy.
What It Is
A Growth Hormone Releasing Hormone (GHRH) analogue that stimulates GH secretion from the anterior pituitary. The No-DAC version (also called Mod GRF 1-29) has a shorter half-life suited to pulsatile dosing; the DAC version extends duration significantly. When combined with Ipamorelin, the two peptides act on separate receptor systems to create a more powerful and sustained GH pulse.
Key Research & Context
- GHRH analogue — works at the upstream hypothalamic-pituitary axis level
- Synergistic with Ipamorelin — the most widely used GH secretagogue combination in functional medicine
- Improved sleep quality, body composition, and collagen synthesis are primary reported benefits
- Buhler's clinic uses this combination regularly as an alternative to exogenous GH
Research context: Included in the FDA compounding ban. Water retention and elevated fasting blood glucose are commonly reported at higher doses. Should be used with periodic IGF-1 monitoring.
Tirzepatide (Mounjaro)
What Was Said on JRE
GLP-1 agonists — semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) — have been discussed in the JRE context as proof that the peptide pharmacology being debated in the grey market has already produced FDA-approved blockbusters. Buhler made this point pointedly: the pharmaceutical industry that lobbied against compounded peptides simultaneously profited from GLP-1 drugs that are themselves peptides. Rogan and Buhler discussed the concern about muscle mass loss on GLP-1s — the phenomenon where rapid fat loss also pulls lean tissue — and what peptide interventions (particularly GH secretagogues) might help preserve muscle during GLP-1 cycles.
What It Is
A dual GIP/GLP-1 receptor agonist — the first of its class. By activating both receptors simultaneously, tirzepatide produces greater weight loss than GLP-1 monotherapy. It is FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (obesity). The SURMOUNT-1 trial showed an average 20.9% body weight reduction at the highest dose over 72 weeks.
Key Research & Context
- FDA-approved prescription medication — the clearest example of a peptide drug reaching mainstream medicine
- Buhler used it as a case study of pharma's selective peptide advocacy
- Muscle mass loss during GLP-1 cycles is a key concern — Rogan has discussed stacking GH peptides to counter this
- Tirzepatide outperforms semaglutide in head-to-head weight loss comparisons
Research context: Prescription-only medication. Nausea, GI distress, and muscle mass loss are documented concerns. Compounded versions require verified sourcing for accurate dosing. Not a research-only compound — this one has full FDA approval.
GHK-Cu (Copper Peptide)
What Was Said on JRE
Buhler introduced the concept of the "Glow Stack" (sometimes called the "KLOW Stack") — a combination of the Wolverine Stack with GHK-Cu and KPV added for skin and tissue quality. GHK-Cu was described as a peptide that increases wound healing, decreases scarring, and helps regenerate collagen — adding a cosmetic and tissue-quality dimension to an otherwise injury-focused stack. Buhler noted that patients adding GHK-Cu reported visible improvements in skin quality, which created a word-of-mouth effect in his clinic well before mainstream awareness.
What It Is
A naturally occurring copper peptide found in human plasma. GHK-Cu stimulates collagen I, III, and VI synthesis, promotes wound healing via fibroblast and keratinocyte migration, reduces inflammatory signaling, and modulates gene expression across thousands of aging-related genes. Clinical studies have demonstrated statistically significant improvement in skin laxity and fine lines versus placebo.
Key Research & Context
- Core component of the "Glow" / "KLOW" stack described by Buhler on JRE
- Collagen synthesis and skin quality improvement — backed by double-blind clinical data
- Wound healing and angiogenesis effects beyond cosmetic applications
- Modulation of 4,000+ genes toward a more youthful expression pattern (Pickart & Margolina 2012)
Research context: Most compelling skin data comes from topical formulation studies. Injectable forms are less characterized for systemic dosing. Some copper accumulation concern with prolonged high-dose injectable use.
MOTS-C
What Was Said on JRE
MOTS-C entered the JRE sphere as part of the broader longevity and mitochondrial health conversation that both Rogan and his guests have increasingly pursued. It is frequently described in the community that follows Rogan's health discussions as "exercise in a vial" — a term that captures its most striking property: the ability to activate AMPK and improve energy metabolism in ways that mimic the cellular adaptations of physical training. Buhler and others in this space have noted its particular relevance for patients who are physically limited and cannot exercise effectively, as well as for high-performers seeking another margin of aerobic capacity.
What It Is
A mitochondria-derived peptide encoded within the 16S rRNA gene of the mitochondrial genome. MOTS-C activates AMPK — the cellular energy sensor — and improves mitochondrial function, insulin sensitivity, and metabolic flexibility. Circulating levels decline with age, and it has been studied for exercise performance, insulin resistance, sarcopenia prevention, and longevity.
Key Research & Context
- "Exercise in a vial" — AMPK activation mimics metabolic adaptations of physical training
- Improved VO2 max and exercise tolerance documented in primate research
- Insulin sensitization independent of caloric restriction in animal models
- Age-related muscle function preservation — directly relevant to the sarcopenia-on-GLP-1s concern
Research context: Human clinical data is emerging but limited. Optimal human dosing is not established. Most robust evidence from rodent and primate studies. Short plasma half-life of native peptide means dosing frequency matters.
Thymosin Alpha-1
What Was Said on JRE
Thymosin Alpha-1 was part of Rogan's stated personal peptide protocol — BPC-157, Ipamorelin, and Thymosin Alpha-1 — as described in his 2022 Flagrant podcast appearance. Rogan spoke positively about it for immune system support and overall recovery, particularly when training volume is high and the immune system is under increased load. Buhler placed it in the category of peptides with the strongest immune-modulating evidence base, noting its long history in oncology and infectious disease research.
What It Is
A 28-amino-acid peptide derived from prothymosin alpha, naturally produced by the thymus gland. Thymosin Alpha-1 modulates both innate and adaptive immunity — it matures T-lymphocytes, enhances NK cell activity, and upregulates MHC class I expression. It is FDA-approved in several countries as Zadaxin for hepatitis B and C, and has been studied in cancer, sepsis, and post-COVID immune dysregulation.
Key Research & Context
- Part of Rogan's personal stated peptide stack alongside BPC-157 and Ipamorelin
- FDA-approved as Zadaxin in multiple countries — one of the few peptides with genuine regulatory approval
- Studied in hepatitis B and C, cancer adjunct therapy, and sepsis management
- Immune normalization in both immunodeficient and autoimmune contexts — bidirectional modulation
Research context: Not FDA-approved for the wellness/performance uses discussed on JRE — those applications are outside the approved indication. Best-characterized as an immune therapy, not a performance enhancer, despite off-label use in that space.
Dihexa
What Was Said on JRE
Buhler shared his personal experience with Dihexa in JRE #2079, describing notable improvements in neurocognitive function — specifically memory and processing clarity. He positioned it within the category of peptides with a compelling mechanism that has largely escaped mainstream medical attention due to the same patent-economics dynamic he describes for the rest of the peptide class. It was one of the more striking personal testimonials in the episode precisely because it came from a healthcare professional describing his own experience rather than a patient case.
What It Is
An angiotensin IV analog developed at Washington State University with an extraordinary potency for inducing synaptogenesis — the formation of new neural synaptic connections. In animal studies, Dihexa has outperformed BDNF by several orders of magnitude in promoting new neuronal connections. It crosses the blood-brain barrier and appears to work via HGF/c-Met signaling in the hippocampus.
Key Research & Context
- Buhler's personal use — reported significant neurocognitive improvement
- Synaptogenesis — rebuilding synaptic connections rather than simply enhancing existing ones
- Outperforms BDNF by orders of magnitude in animal synaptogenesis assays
- Potential applications in Alzheimer's, TBI recovery, and age-related cognitive decline
Research context: Research is primarily from animal studies. No published human clinical trial data as of 2025. The potency of its neuroplasticity effects also raises theoretical questions about unintended downstream effects. Transdermal formulation has better bioavailability than oral for most users.
MK-677 (Ibutamoren)
What Was Said on JRE
Buhler cited MK-677 (Ibutamoren) as a telling example of how the regulatory and pharmaceutical landscape around peptides works in practice. He noted that MK-677 appeared on the FDA's compounding ban list — but simultaneously, a pharmaceutical company had it in Phase 2 FDA trials. His point was blunt: the same compound was "banned" for compounding pharmacies while being commercially developed by pharma. MK-677 stimulates GH release via the ghrelin receptor, similar to Ipamorelin but taken orally rather than injected — making it particularly accessible and popular in the broader health community.
What It Is
An orally active, non-peptide growth hormone secretagogue that mimics the action of ghrelin at the GHS-R1a receptor. Unlike injectable GHRPs, MK-677 is taken orally, has a 24-hour half-life enabling once-daily dosing, and produces sustained elevation in GH and IGF-1 levels. It has been studied for muscle wasting, bone density, and cognitive function in clinical trials.
Key Research & Context
- Oral bioavailability — the only GH secretagogue that can be taken by mouth effectively
- 24-hour half-life — once-daily dosing vs. multiple daily injections for injectable GHRPs
- Buhler used it to illustrate the pharma/FDA conflict of interest around peptide access
- Clinical trials for muscle wasting (sarcopenia) and Alzheimer's have been completed with positive signals
Research context: Water retention and increased appetite are common and can be significant. Elevated fasting glucose is a documented concern — not recommended for pre-diabetic individuals without monitoring. Regulatory status is complex — technically a SARM precursor and not a peptide, which affects its legal category in some jurisdictions.
Huberman's Honest Caveats — Worth Repeating
What distinguished Andrew Huberman's contributions to these episodes from typical peptide advocacy was his consistent willingness to name the limits of the evidence base. He stated explicitly that BPC-157 has "no clinical data — it's all animals." He noted a theoretical concern that compounds stimulating tissue growth and angiogenesis could theoretically feed existing tumors through the same mechanisms. He described the grey market status of most peptides as a genuine problem — not because the compounds are necessarily dangerous, but because the absence of regulated clinical investigation leaves both patients and practitioners making decisions without the data they should have.
He also noted that there is "a whole class of peptides that are not hormones but stimulate hormones — and significantly enhance performance," while warning that tinkering with hormonal systems in parallel carries risks that are not always front of mind when someone is enthusiastic about a new compound.
These caveats are worth holding alongside the enthusiasm these episodes generated. The peptides discussed here are genuinely interesting research compounds with compelling mechanistic rationales. The honest position is that most of them deserve more clinical investigation than they have received — and that the regulatory environment, as Buhler argues persuasively, has actively impeded that investigation.
Other Articles
Calculator
Calculate exact reconstitution volumes and insulin unit doses for any peptide protocol.
Open Calculator →